GNLX
Genelux Corporation
NASDAQ · USHealthcareBiotechnology
$2.93+2.09%
Price as of Jul 20, 2026
GNLX valuation
Genelux Corporation valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 9.72x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.73x
- Price / sales
- —
- Price / cash flow
- -5.07x
Enterprise value
- Enterprise value
- $107.7M
- EV / sales
- —
- EV / EBITDA
- -3.36x
- EV / EBIT
- -3.19x
- Market cap
- $131.4M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.